Prostate Cancer

Higher BMI Increases PCa Death Risk

ORLANDO—Elevated BMI is in-dependently associated with higher prostate cancer-specific mortality (PCSM) following radiation therapy and androgen suppression in men with locally advanced prostate cancer.

CRP Predicts Advanced PCa Outcomes

ORLANDO—Blood levels of C-reactive protein (CRP) independently predict survival in men with metastatic androgen-independent prostate cancer (AIPC), researchers conclude. CRP levels also predict the likelihood that patients will respond to therapy.

Fast Track for New Prostate Cancer Therapy

The FDA has assigned priority review status to the Biologics License Application for Provenge (sipuleucel-T), an investigational immunotherapy for asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.

Screening Cuts Risk of Advanced PCa

Biennial PSA screening decreases the likelihood of being diagnosed with metastatic prostate cancer, but nearly doubles the chance of being diagnosed with prostate cancer of any type, a Swedish sudy found.

Next post in News